Among the funded projects is Prof. Andrew Bateman’s work at The Institute on a novel biologic therapy that aims to slow or stabilize the progression of ALS
CQDM and Brain Canada are proud to announce funding for five large-scale collaborative research projects that bring together academic, clinical and industry partners across the country. These projects aim to transform promising scientific advances into concrete medical innovations. Funding has been made possible through grants from the Government of Québec, administered by CQDM, totaling of $2,452,745, with additional support from several industry partners, matched by a $2,961,693 contribution from Brain Canada, through the Canada Brain Research Fund (CBRF).
An innovative biologic therapy for amyotrophic lateral sclerosis (ALS): This project, with a total value of $881,122, is led by Andrew Bateman, PhD, (Research Institute of the McGill University Health Centre) in partnership with company Neurodyn Life Sciences Inc.